---
layout: ../../layouts/Article.astro
title: "BPC-157: A Complete Evidence-Based Guide"
description: "A science-backed guide to BPC-157 (Body Protection Compound-157) covering mechanisms of action, research-backed benefits, dosage protocols, reconstitution, side effects, and legal status."
image: /images/articles/bpc-157.webp
date: 2026-02-13
category: "Peptide Guides"
tags: ["BPC-157", "body protection compound", "peptides", "gut healing", "tendon repair", "neuroprotection", "research peptides"]
author: "PeptideRundown Team"
---

# <a href="/articles/bpc-157-complete-guide">BPC-157</a>: A Complete Evidence-Based Guide

**<a href="/articles/bpc-157-complete-guide">BPC-157</a>** stands as one of the most fascinating peptides in modern research, earning its reputation through over two decades of published studies that suggest remarkable healing properties. This synthetic 15-amino-acid compound, derived from a protein naturally found in human gastric juice, has captured the attention of athletes, clinicians, and researchers worldwide for its potential benefits ranging from gut healing to tendon repair.

The science behind this peptide is both compelling and complex. Animal studies consistently show accelerated healing across multiple tissue types, from gastrointestinal ulcers to tendon injuries, suggesting mechanisms that work at fundamental levels of cellular repair and regeneration.

What makes **BPC-157** particularly intriguing isn't just its apparent effectiveness, but its unique stability in gastric acid and its ability to modulate multiple healing pathways simultaneously. Unlike many therapeutic peptides that target single mechanisms, this compound appears to orchestrate coordinated healing responses involving blood vessel formation, growth factor upregulation, and cellular signaling optimization.

The most commonly referenced human-equivalent dose falls between **250-500 mcg** once or twice daily via subcutaneous injection, extrapolated from extensive animal research. However, it's critical to understand that no large-scale human clinical trials exist as of early 2026, and the FDA has placed significant restrictions on its availability through compounding pharmacies in the United States.

## What Is BPC-157?

BPC-157, formally known as Body Protection Compound-157, is a synthetic pentadecapeptide consisting of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. This specific sequence represents a partial fragment of a larger protein naturally found in human gastric juice, where it appears to play a role in maintaining the integrity of the gastrointestinal lining.

The "body protection compound" designation reflects its origin from this protective gastric protein. Researchers isolated and synthesized this particular 15-amino-acid sequence after discovering it possessed concentrated biological activity that could be studied and potentially applied therapeutically.

What sets BPC-157 apart from most other peptides is its remarkable stability in harsh environments, particularly gastric acid. While most peptides break down rapidly when exposed to stomach acid, BPC-157 maintains its structure and biological activity, making it a candidate for both injectable and oral administration in research settings.

The compound was first characterized and extensively studied by researchers at the University of Zagreb in Croatia, led by Professor Predrag Sikiric. His laboratory has contributed over 100 peer-reviewed papers on BPC-157 since the early 1990s, creating the foundation of knowledge we have about this peptide today [1].

| Property | Detail |
|---|---|
| Type | Synthetic pentadecapeptide (15 amino acids) |
| Molecular Weight | ~1,419 Da |
| Origin | Partial sequence of human gastric juice protein BPC |
| Primary Research | Preclinical (animal models, in vitro) |
| Human Trials | Limited; no completed large-scale RCTs as of early 2026 |
| FDA Status | Not approved for human use |

## How BPC-157 Works: Mechanisms of Action

The mechanisms through which BPC-157 exerts its effects are sophisticated and multifaceted, involving several key biological pathways that work together to promote healing and tissue protection. Rather than acting through a single mechanism, this peptide appears to coordinate multiple healing processes simultaneously.

At the cellular level, BPC-157's most well-documented effect involves promoting angiogenesis, the formation of new blood vessels. Research demonstrates that it upregulates vascular endothelial growth factor (VEGF) expression and activates the VEGF-VEGFR2 signaling pathway [2, 3]. This enhanced blood vessel formation translates directly into improved tissue oxygenation and nutrient delivery, creating optimal conditions for healing across diverse tissue types.

The peptide's interaction with the nitric oxide system represents another key mechanism that sets it apart from simple agonists or antagonists. Rather than pushing NO activity in one direction, BPC-157 acts as a modulator, capable of countering both NO excess and NO deficiency [4]. This sophisticated regulation is particularly significant because dysregulated NO signaling contributes to conditions ranging from gastrointestinal ulcers to cardiovascular dysfunction.

BPC-157 also influences multiple growth factors beyond VEGF, including epidermal growth factor (EGF) involved in mucosal healing, hepatocyte growth factor (HGF) relevant to liver and tissue repair, and fibroblast growth factor (FGF) critical for connective tissue maintenance [5]. This broad growth factor engagement may explain why the peptide appears effective across such diverse tissue types.

At the cellular signaling level, BPC-157 activates the FAK-paxillin pathway, which plays essential roles in cell migration, adhesion, and tissue remodeling during wound healing and repair processes [6]. Additionally, the peptide demonstrates interactions with dopaminergic and GABAergic systems, showing protective effects against neurotoxicity and potential anxiolytic-like effects in animal models [7, 8].

## What BPC-157 Can Do: Research-Backed Benefits

The evidence base for BPC-157 spans numerous tissue types and conditions, though it's important to note that the vast majority comes from preclinical studies in animal models. While this research is extensive and consistently positive, human clinical data remains very limited.

### Gastrointestinal Healing

Given its origin from gastric juice, BPC-157's strongest evidence base involves gastrointestinal applications. Animal studies have demonstrated accelerated healing of gastric, duodenal, and colonic ulcers caused by NSAIDs, alcohol, stress, and surgical procedures [1, 9]. The peptide doesn't just promote healing—it appears to actively protect against damage while repair processes occur.

In inflammatory bowel disease models, BPC-157 reduced inflammation markers, promoted mucosal healing, and improved clinical scores at levels comparable to standard treatments [10]. Studies of surgical gut healing showed faster anastomosis recovery and reduced adhesion formation [11]. Perhaps most practically relevant, the peptide demonstrated protective effects against acid reflux-induced esophageal damage, suggesting potential applications for GERD and related conditions [9].

### Tendon and Ligament Repair

The tendon-healing properties of BPC-157 have generated intense interest in athletic and sports medicine communities, and for good reason. In controlled Achilles tendon studies, the peptide significantly accelerated healing of transected tendons in rats, with treated animals showing improved biomechanical properties and more organized collagen fiber formation compared to controls [12].

Similar acceleration was demonstrated in medial collateral ligament injury models, where BPC-157 treatment resulted in faster return to normal function [13]. These effects appear mediated through increased collagen production, enhanced tendon fibroblast proliferation, and activation of the FAK-paxillin pathway, combined with improved blood supply to the injury site [6, 12].

### Muscle and Bone Healing

BPC-157 has shown positive effects across multiple muscle injury models, including accelerated recovery from crush injuries, improved healing of surgically transected muscles, and protective effects against muscle wasting associated with systemic conditions [14]. The peptide appears to optimize the inflammatory response while promoting proper tissue remodeling.

Bone healing research, while more limited, shows promising results in rabbit models with segmental bone defects. Animals treated with BPC-157 demonstrated improved bone callus formation and faster radiographic healing compared to controls [15]. These effects likely relate to the peptide's angiogenic properties and growth factor modulation.

### Neuroprotection

The neuroprotective properties of BPC-157 extend well beyond simple tissue healing. In traumatic brain injury studies, treated animals showed reduced brain edema, improved behavioral outcomes, and enhanced neuronal survival following controlled injuries [16]. For peripheral nerve damage, the peptide accelerated nerve regeneration and improved functional recovery after sciatic nerve crush injuries [17].

Perhaps most intriguingly, BPC-157 demonstrated protective effects against dopaminergic neurotoxicity in models relevant to Parkinson's-like pathology [7]. It also showed antidepressant-like effects through interactions with the serotonin system [8]. While these findings are preliminary, they suggest potential applications beyond traditional tissue healing.

### Cardiovascular and Systemic Effects

BPC-157's cardiovascular effects demonstrate its modulatory nature rather than simple stimulation or inhibition. Animal studies show it can counter both hypertensive and hypotensive states, suggesting a blood pressure normalizing effect rather than directional change [4]. The peptide also demonstrated anti-arrhythmic properties, successfully countering digitalis-induced heart rhythm disturbances [18].

Additional systemic benefits include hepatoprotective properties against alcohol-induced liver injury and NSAID-induced liver toxicity [19]. One of BPC-157's most consistently demonstrated effects across studies is protection against the damaging effects of NSAIDs on multiple organ systems, including the gastric mucosa, intestinal lining, liver, and brain [1, 9].

## BPC-157 Dosage: How Much to Take

Most current protocols reference dosages between **250-500 mcg** once or twice daily via subcutaneous injection, typically administered for 4-8 week cycles. These recommendations are extrapolated from animal studies using allometric scaling, which provides a reasonable starting point but isn't perfect for cross-species translation.

The human-equivalent dose calculations typically fall in the range of 200-500 mcg per administration, corresponding to approximately 2.5-10 mcg/kg when calculated on a body-weight basis. Duration protocols commonly run 4-8 weeks, though there's no established evidence-based cycling protocol from controlled studies.

| Parameter | Range |
|-----------|-------|
| Typical dose | 200-500 mcg per administration |
| Frequency | 1-2 times daily |
| Duration | Typically 4-8 weeks |
| Body-weight equivalent | ~2.5-10 mcg/kg (extrapolated from rodent studies) |

Subcutaneous injection represents the most common route for systemic effects, with many protocols recommending administration near the site of injury when targeting specific tissues. However, animal studies have demonstrated systemic effects even with administration at distant sites, suggesting the peptide circulates effectively throughout the body.

Oral administration is discussed primarily for gastrointestinal applications, taking advantage of BPC-157's unusual stability in gastric acid [1]. This route may be particularly relevant for gut-related conditions, though bioavailability questions remain for non-GI targets.

Some practitioners discuss cycling protocols alternating 4-6 weeks of use with breaks, but this approach is based on clinical judgment rather than controlled trial data. The optimal administration schedule remains to be established through formal human studies.

## How to Reconstitute BPC-157 (Step-by-Step)

BPC-157 typically arrives as a lyophilized powder in a sealed vial that requires reconstitution with sterile solvent before use. The most common solvent is bacteriostatic water containing 0.9% benzyl alcohol as a preservative, which extends the shelf life of the reconstituted solution.

For precise measurements, use our free <a href="/articles/peptide-dosing-calculator-reconstitution-math">Peptide Reconstitution Calculator</a>, or see our thorough <a href="/articles/how-to-reconstitute-peptides">reconstitution guide</a> for detailed instructions.

Start by gathering your materials: the BPC-157 vial, bacteriostatic water, insulin syringes (typically 1 mL), and alcohol swabs. Clean both vial tops with alcohol swabs and allow them to dry completely before proceeding.

For standard concentrations, draw the appropriate amount of bacteriostatic water into your syringe. Common ratios include 5 mg vial plus 2 mL BAC water, creating 2,500 mcg/mL concentration where each 0.1 mL equals 250 mcg. Alternatively, 5 mg vial plus 1 mL BAC water creates 5,000 mcg/mL concentration where each 0.1 mL equals 500 mcg.

Inject the water slowly into the BPC-157 vial, directing the stream against the glass wall rather than directly onto the powder to avoid foaming. Swirl the vial gently until the powder fully dissolves—avoid vigorous shaking, which can damage the peptide structure.

Store the reconstituted solution in the refrigerator at 2-8°C and avoid freezing once reconstituted. The solution should remain stable for 3-4 weeks when stored properly.

| State | Storage | Shelf Life |
|---|---|---|
| Lyophilized (unreconstituted) | Refrigerated or frozen | Months to years |
| Reconstituted (BAC water) | Refrigerated (2-8°C) | 3-4 weeks |

Avoid repeated freeze-thaw cycles, direct sunlight, and temperatures above 8°C for extended periods to maintain peptide integrity.

## BPC-157 Side Effects and Safety Profile

BPC-157 has demonstrated a remarkably favorable safety profile throughout its extensive preclinical research history. Animal studies have failed to establish a lethal dose even at extremely high concentrations, with no mortality observed in acute toxicity testing [1]. Subchronic studies at therapeutic and supratherapeutic doses have shown no organ toxicity, and no mutagenic or carcinogenic effects have been reported in the existing literature.

Community reports and limited clinical observations suggest that side effects in humans are generally mild and infrequent when they occur. These may include occasional mild nausea (more common with oral administration), rare instances of dizziness or lightheadedness, minor injection site reactions such as redness and mild discomfort, infrequent headaches, and rare reports of fatigue or lethargy.

**SAFETY WARNING: Important considerations exist despite the favorable profile.** The limited human data means no large-scale clinical trials have established definitive safety parameters for human use. The peptide's blood vessel promoting properties could be problematic for individuals with active cancer, as enhanced angiogenesis might support tumor growth [2].

Long-term effects remain unknown since most studies examine acute or short-term use patterns. Source quality varies significantly in the unregulated peptide market, where contamination and mislabeling represent real concerns. The peptide's effects on NO, dopaminergic, and other systems may interact with prescription medications.

Anyone with active malignancies or taking prescription medications should consult a knowledgeable physician before considering BPC-157 use.

## Is BPC-157 Legal? Current Regulatory Status

The legal environment for BPC-157 in the United States has become increasingly restrictive over recent years. The peptide has never been approved by the FDA as a pharmaceutical drug and hasn't completed the formal approval process for any medical indication.

Between 2022-2024, the FDA issued warning letters to companies marketing BPC-157 for human use, particularly targeting those making specific therapeutic claims. In late 2023 and continuing through 2024-2025, the FDA placed BPC-157 on its list of substances prohibited from use in compounding under sections 503A and 503B, citing insufficient safety and efficacy data for human use.

The peptide remains available as a research chemical designated for in vitro research and non-human use only. Personal use exists in a regulatory gray area—purchasing research peptides isn't explicitly illegal, but self-administration falls outside FDA-sanctioned use patterns.

International availability varies considerably by jurisdiction. Canada offers some access through compounding pharmacies operating under different regulatory frameworks than the US. The European Union hasn't approved BPC-157 as a pharmaceutical product, though it's available in some countries as a research compound. Australia regulates it under the TGA with prescription-level requirements.

For athletes, BPC-157 doesn't currently appear on the WADA Prohibited List as of 2025, but competitive athletes should verify status regularly since prohibited substance lists can change.

Regulatory status can shift rapidly in this space. Always verify current regulations in your jurisdiction before purchasing or using any research peptide.

## Frequently Asked Questions

### Is BPC-157 natural?

This question has a nuanced answer. BPC-157 is a synthetic peptide, but its amino acid sequence derives directly from a naturally occurring protein found in human gastric juice. The specific 15-amino-acid sequence doesn't exist as a standalone molecule in the body, making it both natural in origin and synthetic in production and application.

### How quickly does BPC-157 work?

Animal studies document measurable effects on tissue healing parameters within days of treatment initiation, with significant improvements typically observed over 1-4 week periods. Anecdotal reports from human use are broadly consistent with this timeline, though individual responses vary considerably based on the condition being addressed, dosing protocol, and individual factors.

### Can BPC-157 be taken orally?

Yes, and this represents one of BPC-157's unique properties among therapeutic peptides. It demonstrates remarkable stability in gastric acid and has shown efficacy via oral administration in animal studies, particularly for gastrointestinal applications [1]. For non-GI targets, subcutaneous injection is more commonly discussed and may offer superior bioavailability.

### Does BPC-157 need to be injected near the injury site?

This remains a subject of ongoing debate among practitioners and researchers. Some protocols recommend local (perilesional) injection near injured tissue, theorizing that higher local concentrations may enhance healing effects. However, animal studies have demonstrated systemic benefits even with administration at sites distant from the target tissue [1]. The optimal approach likely depends on the specific application and individual goals.

### Can BPC-157 be stacked with other peptides?

BPC-157 is frequently discussed in combination with <a href="/articles/tb-500-complete-guide">TB-500 (Thymosin Beta-4 fragment)</a> for tissue healing applications. While both peptides promote healing through overlapping but distinct mechanisms—BPC-157 focusing on angiogenesis and growth factor upregulation, TB-500 emphasizing cell migration and tissue remodeling—no controlled studies have examined this combination in humans. The theoretical rationale appears sound, but evidence remains anecdotal.

### Is BPC-157 safe for long-term use?

This question can't be answered definitively with current data. Existing safety information comes from relatively short-term animal studies, and the theoretical concern about enhanced angiogenesis is particularly relevant for chronic administration patterns. The lack of long-term safety data in any species means extended use involves unknown risk profiles.

### Will BPC-157 show up on a drug test?

Standard workplace drug panels don't test for BPC-157 or other research peptides. Advanced peptide-specific testing, as might be employed by some sports organizations, could potentially detect it. Athletes subject to competitive testing should consult their sport's governing body and verify current testing protocols before use.

## What We Still Don't Know About BPC-157

Several significant knowledge gaps remain in BPC-157 research that affect how we should interpret existing data and approach potential applications. The concentration of research from a single group (Sikiric et al., University of Zagreb) has produced the majority of published studies, and broader independent replication would significantly strengthen the evidence base.

As of early 2026, no completed large-scale randomized controlled trials in humans exist. This represents the most critical limitation in translating promising animal research to human applications with confidence. Dose translation from rodent models to humans using allometric scaling is imperfect and may not account for species-specific differences in metabolism, receptor sensitivity, and pharmacokinetics.

Long-term safety profiles in any species aren't well characterized, and the chronic effects of sustained BPC-157 administration remain unknown. The relative contribution of different mechanisms to observed effects isn't fully understood—while we know BPC-157 affects multiple pathways, we don't know which are most important for specific applications.

These gaps don't invalidate the existing research, which is substantial and generally well-conducted within its limitations. However, they underscore the importance of approaching BPC-157 with appropriate caution and intellectual honesty about what we do and don't know.

## Summary

BPC-157 represents one of the most extensively studied research peptides, with a substantial preclinical evidence base suggesting benefits across multiple healing applications. Its mechanisms involve coordinated effects on angiogenesis, nitric oxide modulation, growth factor upregulation, and cellular signaling pathways that work together to promote tissue repair and protection.

The preclinical safety profile appears favorable, with no lethal dose established in extensive animal testing and no significant organ toxicity observed at therapeutic doses. However, the absence of large-scale human clinical trials means we can't make definitive efficacy and safety claims for human applications. The theoretical concern regarding enhanced angiogenesis in individuals with active cancer deserves particular attention.

Regulatory restrictions continue increasing, particularly in the United States where compounding pharmacy access has been significantly limited as of 2025-2026. The <a href="/articles/are-peptides-legal-fda-regulations-2026">peptide remains available as a research chemical</a>, though this status continues evolving. International availability varies considerably by country and regulatory framework.

For anyone considering BPC-157, consultation with a knowledgeable healthcare provider is strongly recommended. This peptide represents a fascinating example of how natural compounds can inspire synthetic therapeutics, but the translation from promising animal research to human application requires careful consideration of both potential benefits and unknown risks.

The research suggests genuine therapeutic potential, but the limitations of current data demand a thoughtful approach. As with all research peptides, the gap between laboratory promise and real-world application should inform decision-making.

New to peptides? Start with our <a href="/articles/what-are-peptides-beginners-guide">beginner's guide to peptide therapy</a>. You can also learn about <a href="/articles/peptide-side-effects-what-to-know">peptide side effects</a> and <a href="/articles/how-to-store-peptides">how to store peptides properly</a>.

## References

- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. *Curr Pharm Des.* 2014;20(7):1126-1135. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23829361/)

- Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. *J Mol Med.* 2017;95(3):323-333. [PubMed](https://pubmed.ncbi.nlm.nih.gov/27900448/)

- Tkalcevic VI, Cuzic S, Brajsa K, et al. Enhancement by PL 14736 of granulation and collagen organization in healing wounds. *Eur J Pharmacol.* 2007;570(1-3):212-221. [PubMed](https://pubmed.ncbi.nlm.nih.gov/17628536/)

- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. *Front Pharmacol.* 2018;9:1408.

- Vukojevic J, Siroglavic M, Kasnik K, et al. Rat inferior caval vein (ICV) ligature and particular pentadecapeptide BPC 157 therapy. *Vasc Pharmacol.* 2018;106:46-57. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29501668/)

- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. *J Appl Physiol.* 2011;110(3):774-780. [PubMed](https://pubmed.ncbi.nlm.nih.gov/21030672/)

- Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease. *Inflammopharmacology.* 2006;14(5-6):214-221. [PubMed](https://pubmed.ncbi.nlm.nih.gov/17091493/)

- Sikiric P, Rucman R, Turkovic B, et al. Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. *Curr Pharm Des.* 2018;24(18):1990-2001. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29756564/)

- Sikiric P et al. *Life Sci.* 1994;54(5):PL63-68. [PubMed](https://pubmed.ncbi.nlm.nih.gov/8163129/)

- Cesarec V, Becejac T, Misic M, et al. Pentadecapeptide BPC 157 and the esophagocutaneous fistula healing therapy. *Eur J Pharmacol.* 2013;701(1-3):203-212. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23220707/)

- Skorjanec S, Dolovski Z, Kocman I, et al. Therapy for unhealed gastrocutaneous fistulas in rats. *Dig Dis Sci.* 2009;54(12):2602-2611. [PubMed](https://pubmed.ncbi.nlm.nih.gov/19117128/)

- Staresinic M, Petrovic I, Novinscak T, et al. Effective therapy of transected quadriceps muscle in rat. *J Orthop Res.* 2006;24(5):1109-1117. [PubMed](https://pubmed.ncbi.nlm.nih.gov/16609979/)

- Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 improves ligament healing in the rat. *J Orthop Res.* 2010;28(9):1155-1161. [PubMed](https://pubmed.ncbi.nlm.nih.gov/20225319/)

- Novinscak T, Brcic L, Staresinic M, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury. *Surg Today.* 2008;38(8):716-725. [PubMed](https://pubmed.ncbi.nlm.nih.gov/18668316/)

- Sebecic B, Nikolic V, Sikiric P, et al. Osteogenic effect of a gastric pentadecapeptide, BPC-157, on healing of segmental bone defect in rabbits. *Bone.* 1999;24(3):195-202. [PubMed](https://pubmed.ncbi.nlm.nih.gov/10071910/)

- Tudor M, Jandric I, Marovic A, et al. Traumatic brain injury in mice and pentadecapeptide BPC 157 effect. *Regul Pept.* 2010;160(1-3):26-32. [PubMed](https://pubmed.ncbi.nlm.nih.gov/19931579/)

- Gjurasin M, Miklic P, Zupancic B, et al. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. *Regul Pept.* 2010;160(1-3):33-41. [PubMed](https://pubmed.ncbi.nlm.nih.gov/19903499/)

- Barisic I, Balenovic D, Klicek R, et al. Mortal hyperkalemia disturbances in rats are NO-system related. *Regul Pept.* 2013;181:16-26. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23318498/)

- Ilic S, Brcic I, Mester M, et al. Over-dose insulin and stable gastric pentadecapeptide BPC 157. *J Physiol Pharmacol.* 2009;60 Suppl 7:107-114. [PubMed](https://pubmed.ncbi.nlm.nih.gov/20388953/)

*Last updated: February 13, 2026*

*This article is maintained by the PeptideRundown Team and updated as new research becomes available. If you find an error or have a suggestion, [contact us](/contact).*

*PeptideRundown.com provides evidence-based educational content about peptides. We do not sell peptides, and we are not affiliated with any peptide supplier. Nothing on this site constitutes medical advice.*